significantTreatment update
PIONEER 3-year follow-up confirms sustained avapritinib benefit in ISM
Systemic Mastocytosis →Summary
Longer-term follow-up of PIONEER trial patients demonstrates that avapritinib maintains its favorable benefit-risk profile after 3+ years of therapy, with continued symptom improvement and mast cell burden reduction. Supports avapritinib as chronic treatment for ISM.
More from Systemic Mastocytosis
significantNew research
Swedish and Danish population-based studies reveal higher SM prevalence than expected
breakthroughTreatment update
Avapritinib FDA-approved for indolent systemic mastocytosis (PIONEER trial)
incrementalTreatment update
Avapritinib molecular responses in advanced SM: 30% achieve D816V undetectable
significantGenetic finding
WHO 2022 and ICC 2022 classification updates published
ID: systemic-mastocytosis-update-1Type: treatment_updateImpact: significant